Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.

Wiehagen KR, Girgis NM, Yamada DH, Smith AA, Chan SR, Grewal IS, Quigley M, Verona RI.

Cancer Immunol Res. 2017 Dec;5(12):1109-1121. doi: 10.1158/2326-6066.CIR-17-0258. Epub 2017 Nov 2.

PMID:
29097420
2.

Increasing angulation decreases measured aortic stent graft pullout forces.

Rahmani S, Grewal IS, Nabovati A, Doyle MG, Roche-Nagle G, Tse LW.

J Vasc Surg. 2016 Feb;63(2):493-9. doi: 10.1016/j.jvs.2014.06.115. Epub 2014 Jul 31.

3.

Posterior spinal cord herniation: a novel occurrence following surgery for an intramedullary cyst at the thoracolumbar junction.

Zakaria R, Ellenbogen JR, Grewal IS, Buxton N.

Eur Spine J. 2013 May;22 Suppl 3:S399-403. doi: 10.1007/s00586-012-2515-5. Epub 2012 Sep 27.

4.

Hip resurfacing revision rates: radiological audit of risk factors.

Grewal IS, Kazi HA, Cope MR.

Ann R Coll Surg Engl. 2011 Oct;93(7):564; author reply 564-5. doi: 10.1308/147870811X598579. No abstract available.

5.

Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.

Lewis TS, McCormick RS, Emmerton K, Lau JT, Yu SF, McEarchern JA, Grewal IS, Law CL.

Clin Cancer Res. 2011 Jul 15;17(14):4672-81. doi: 10.1158/1078-0432.CCR-11-0479. Epub 2011 May 24.

6.

Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells.

Lewis TS, McCormick RS, Stone IJ, Emmerton K, Mbow B, Miyamoto J, Drachman JG, Grewal IS, Law CL.

Leukemia. 2011 Jun;25(6):1007-16. doi: 10.1038/leu.2011.21. Epub 2011 Mar 11.

PMID:
21394099
7.

5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Sutherland MK, Yu C, Anderson M, Zeng W, van Rooijen N, Sievers EL, Grewal IS, Law CL.

MAbs. 2010 Jul-Aug;2(4):440-8. Epub 2010 Jul 1.

8.

Antibody drug-conjugates targeting the tumor vasculature: Current and future developments.

Gerber HP, Senter PD, Grewal IS.

MAbs. 2009 May-Jun;1(3):247-53. Review.

9.

Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Sutherland MK, Yu C, Lewis TS, Miyamoto JB, Morris-Tilden CA, Jonas M, Sutherland J, Nesterova A, Gerber HP, Sievers EL, Grewal IS, Law CL.

MAbs. 2009 Sep-Oct;1(5):481-90. Epub 2009 Sep 15.

10.
11.

Targeting inflammatory cells to improve anti-VEGF therapies in oncology.

Gerber HP, Olazoglu E, Grewal IS.

Recent Results Cancer Res. 2010;180:185-200. doi: 10.1007/978-3-540-78281-0_11. Review.

PMID:
20033384
12.

Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.

Oflazoglu E, Grewal IS, Gerber H.

Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. Review.

PMID:
19760074
13.

Targeting CD70 for human therapeutic use.

Boursalian TE, McEarchern JA, Law CL, Grewal IS.

Adv Exp Med Biol. 2009;647:108-19. doi: 10.1007/978-0-387-89520-8_7. Review.

PMID:
19760069
14.

Targeting of BAFF and APRIL for autoimmunity and oncology.

Ryan MC, Grewal IS.

Adv Exp Med Biol. 2009;647:52-63. doi: 10.1007/978-0-387-89520-8_4. Review.

PMID:
19760066
15.

Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges.

Law CL, Grewal IS.

Adv Exp Med Biol. 2009;647:8-36. doi: 10.1007/978-0-387-89520-8_2. Review.

PMID:
19760064
16.

Overview of TNF superfamily: a chest full of potential therapeutic targets.

Grewal IS.

Adv Exp Med Biol. 2009;647:1-7. doi: 10.1007/978-0-387-89520-8_1. Review.

PMID:
19760063
17.

Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis.

Oflazoglu E, Boursalian TE, Zeng W, Edwards AC, Duniho S, McEarchern JA, Law CL, Gerber HP, Grewal IS.

J Immunol. 2009 Sep 15;183(6):3770-7. doi: 10.4049/jimmunol.0901637. Epub 2009 Aug 26.

18.

Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia.

Law CL, McEarchern JA, Grewal IS.

Clin Lymphoma Myeloma. 2009 Mar;9(1):90-3. doi: 10.3816/CLM.2009.n.024. Review.

PMID:
19362984
19.

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.

Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley SC, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, McDonagh CF, Carter PJ, Benjamin D, Grewal IS.

Blood. 2009 Apr 30;113(18):4352-61. doi: 10.1182/blood-2008-09-179143. Epub 2009 Jan 15.

20.

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.

Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS, Gerber HP.

Br J Cancer. 2009 Jan 13;100(1):113-7. doi: 10.1038/sj.bjc.6604812. Epub 2008 Dec 9.

21.

Preclinical characterization of SGN-70, a humanized antibody directed against CD70.

McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, Grewal IS, Law CL.

Clin Cancer Res. 2008 Dec 1;14(23):7763-72. doi: 10.1158/1078-0432.CCR-08-0493.

22.

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.

Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP.

Clin Cancer Res. 2008 Oct 1;14(19):6171-80. doi: 10.1158/1078-0432.CCR-08-0916. Epub 2008 Sep 22.

23.

CD40 expression on antigen presenting cells and correlation with disease severity in atopic dermatitis.

Oflazoglu E, Simpson EL, Takiguchi R, Hanifin JM, Grewal IS, Gerber HP.

Eur J Dermatol. 2008 Sep-Oct;18(5):527-33. doi: 10.1684/ejd.2008.0495. Epub 2008 Aug 8.

PMID:
18693155
24.

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.

Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP.

Br J Haematol. 2008 Jul;142(1):69-73. doi: 10.1111/j.1365-2141.2008.07146.x. Epub 2008 May 8.

25.

CD70 as a therapeutic target in human malignancies.

Grewal IS.

Expert Opin Ther Targets. 2008 Mar;12(3):341-51. doi: 10.1517/14728222.12.3.341. Review.

PMID:
18269343
26.

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP.

Blood. 2008 Dec 1;112(12):4683-9. doi: 10.1182/blood-2007-04-084525. Epub 2008 Jan 23.

27.

CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity.

Oflazoglu E, Simpson EL, Takiguchi R, Grewal IS, Hanifin JM, Gerber HP.

Eur J Dermatol. 2008 Jan-Feb;18(1):41-9. Epub 2007 Dec 18.

PMID:
18086588
28.

Preclinical safety evaluation of monoclonal antibodies.

Lynch CM, Grewal IS.

Handb Exp Pharmacol. 2008;(181):19-44. Review.

PMID:
18071940
29.

Antibody targeting of B-cell maturation antigen on malignant plasma cells.

Ryan MC, Hering M, Peckham D, McDonagh CF, Brown L, Kim KM, Meyer DL, Zabinski RF, Grewal IS, Carter PJ.

Mol Cancer Ther. 2007 Nov;6(11):3009-18.

30.

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

Oflazoglu E, Stone IJ, Gordon KA, Grewal IS, van Rooijen N, Law CL, Gerber HP.

Blood. 2007 Dec 15;110(13):4370-2. Epub 2007 Oct 1.

31.

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.

McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL.

Blood. 2007 Feb 1;109(3):1185-92. Epub 2006 Oct 12.

32.

Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.

Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, Grewal IS.

Br J Pharmacol. 2006 Aug;148(8):1116-23. Epub 2006 Jul 10. Erratum in: Br J Pharmacol. 2007 Jan;150(2):248.

33.

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC.

Cancer Res. 2005 Dec 15;65(24):11712-20.

34.

TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice.

Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS, Ashkenazi A, Smyth MJ.

Immunol Cell Biol. 2005 Oct;83(5):511-9.

PMID:
16174101
35.

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS.

Cancer Res. 2005 Sep 15;65(18):8331-8. Erratum in: Cancer Res. 2006 Feb 15;66(4):2495.

36.

A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response.

Seshasayee D, Wang H, Lee WP, Gribling P, Ross J, Van Bruggen N, Carano R, Grewal IS.

J Biol Chem. 2004 Jul 16;279(29):30202-9. Epub 2004 May 15.

37.

NTB-A, a new activating receptor in T cells that regulates autoimmune disease.

Valdez PA, Wang H, Seshasayee D, van Lookeren Campagne M, Gurney A, Lee WP, Grewal IS.

J Biol Chem. 2004 Apr 30;279(18):18662-9. Epub 2004 Feb 26.

38.

Role of L-selectin in the development of autoimmune diabetes in non-obese diabetic mice.

Mora C, Grewal IS, Wong FS, Flavell RA.

Int Immunol. 2004 Feb;16(2):257-64.

PMID:
14734611
39.

APRIL-deficient mice have normal immune system development.

Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Erickson S, French D, Schow P, Grewal IS, Ashkenazi A.

Mol Cell Biol. 2004 Feb;24(3):997-1006.

40.

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.

Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC.

Br J Haematol. 2003 May;121(4):592-6.

PMID:
12752100
41.
42.

Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor.

Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS.

Immunity. 2003 Feb;18(2):279-88.

43.

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2.

Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, Grewal IS, Cochran AG, Gordon NC, Yin J, Starovasnik MA, Dixit VM.

Immunity. 2002 Oct;17(4):515-24.

44.

Expression of transgene encoded TGF-beta in islets prevents autoimmune diabetes in NOD mice by a local mechanism.

Grewal IS, Grewal KD, Wong FS, Wang H, Picarella DE, Janeway CA Jr, Flavell RA.

J Autoimmun. 2002 Aug-Sep;19(1-2):9-22.

PMID:
12367555
45.

Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice.

Zhao H, Yan M, Wang H, Erickson S, Grewal IS, Dixit VM.

J Exp Med. 2001 Nov 19;194(10):1441-8.

46.

Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency.

Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S, Cancro M, Grewal IS, Dixit VM.

Curr Biol. 2001 Oct 2;11(19):1547-52.

47.

Activation and accumulation of B cells in TACI-deficient mice.

Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, Tumas D, Grewal IS, Dixit VM.

Nat Immunol. 2001 Jul;2(7):638-43.

PMID:
11429549
48.

TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice.

Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS.

Nat Immunol. 2001 Jul;2(7):632-7.

PMID:
11429548
49.

CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis.

Grewal IS, Foellmer HG, Grewal KD, Wang H, Lee WP, Tumas D, Janeway CA Jr, Flavell RA.

Immunity. 2001 Mar;14(3):291-302.

50.

Response to 'Secreted IgM versus BLyS in germinal center formation'

Ashkenazi A, Grewal IS, Dixit VM.

Nat Immunol. 2000 Sep;1(3):179. No abstract available.

PMID:
10973268

Supplemental Content

Loading ...
Support Center